Transcatheter Valve-in-Valve Pulmonary Valve Implantation Using SAPIEN 3 for a Young-Adult Patient with Severe Heart Failure: A Case Report

Journal of Transcatheter Valve Therapies 2026 Open access

Read full text
Authors: Yuriko Shima, Mike Saji, Satoshi Yazaki, Mamoru Nanasato, Kanako Kishiki, Tomomi Ueda, Tadahiro Yoshikawa, Naoki Wada, Hikoro Matsui
DOI: 10.33290/jtvt.cr.25-0018
Cited by: 0
References: 7

Abstract

Objective: Transcatheter valve-in-valve pulmonary valve implantation (ViV-TPVI) with SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA) is effective for treating insufficient prosthetic valves in right ventricular outflow tract diseases. SAPIEN 3 is primarily used to replace failed aortic valves; therefore, there is limited published data on the outcomes of its use for ViV-TPVI. In patients with severe heart failure, every procedure can lead to collapse during TPVI. This case report aims to describe the procedural strategy, perioperative management, and short-term outcomes of ViV-TPVI with SAPIEN 3 in a patient with biventricular heart failure, where careful preparation and prerisk assessment were critical to procedural success.

Fields of Study & Subjects

Congenital Heart Disease Studies Cardiac Valve Diseases and Treatments Pulmonary Hypertension Research and Treatments

Publication details

Journal / source
Journal of Transcatheter Valve Therapies
Volume
8
Issue
1
Pages
25–30
Publication date
1 January 2026
Language
EN